Occurrence of tinnitus and peripheral sensory neuropathy in women during chemotherapy treatment of breast cancer
Article Sidebar
Published:
Mar 16, 2021
Keywords:
breast neoplasms, drug-related side effects and adverse reactions, drug therapy, ototoxicity, tinnitus
Main Article Content
Abstract
Objective: To analyze the occurrence of tinnitus and peripheral sensory neuropathy in women during breast cancer chemotherapy. Methods: This is a retrospective analytical study with a quantitative approach, performed in medical records of an oncology outpatient service between February 2014 and February 2015, using the toxicities scores of Common Terminology Criteria for Adverse Events (CTCAE). Results: Considering 181 patients with breast cancer who met the inclusion criteria, 49.2% reported tinnitus at some point of the treatment, while 65.1% peripheral sensory neuropathy. In both conditions, the predominant severity score was grade 1, with frequencies of 23.8% and 33.1%, respectively. A significant, positive and weak correlation was observed between the severity of tinnitus and peripheral sensory neuropathy (ρ = 0.325 and p = 0.001), as well as very weak between the number of complete cycles of chemotherapy and tinnitus (ρ = 0.195 and p = 0.009) and neuropathy peripheral sensory (ρ = 0.237 and p = 0.002). Conclusions: Tinnitus and peripheral sensory neuropathy were frequent toxicities during chemotherapy treatment of breast cancer, and both manifested with low severity/functional impact in most participants.
Article Details
How to Cite
1.
Kameo SY, Barbosa-Lima R, Duarte JL, Amorim BF, Silva GM, Marinho PML, Sawada NO. Occurrence of tinnitus and peripheral sensory neuropathy in women during chemotherapy treatment of breast cancer. Health Sci J [Internet]. 2021Mar.16 [cited 2024Apr.28];11(1):69-. Available from: https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1089
Section
ORIGINAL ARTICLE
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors maintain copyright and grant the Health Sciences Journal the right to first publication. From 2024, the publications wiil be licensed under Attribution 4.0 International 
, allowing their sharing, recognizing the authorship and initial publication in this journal.
Authors are authorized to assume additional contracts separately for the non-exclusive distribution of the version of the work published in this journal (e.g., publishing in an institutional repository or as a book chapter), with acknowledgment of authorship and initial publication in this journal.
Authors are encouraged to publish and distribute their work online (e.g., in institutional repositories or on their personal page) at any point after the editorial process.
Also, the AUTHOR is informed and consents that the Health Sciences Journal can incorporate his article into existing or future scientific databases and indexers, under the conditions defined by the latter at all times, which will involve, at least, the possibility that the holders of these databases can perform the following actions on the article.
References
Nico JD, Bertagnolli AC, Rodrigues RO, Primo J, Prata VM, Guzzo LS. Estadiamento do câncer de mama em mulheres atendidas em um centro de referência em oncologia. Arq Ciênc Saúde UNIPAR. 2016;20(2):117-22. https://doi.org/10.25110/arqsaude.v20i2.2016.5313
Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2020: incidência de Câncer no Brasil [Internet]. Rio de Janeiro: INCA; 2019 [cited 2020 Nov 20]. Available from: https://bit.ly/3kshkwy
Ferreira RC, Franco LFR. Efeitos colaterais decorrentes do tratamento quimioterápico no câncer de mama: revisão bibliográfica. Rev Univ Vale Rio Verde. 2017;15(2):633-8. https://doi.org/10.5892/ruvrd.v15i2.3759
Hirose Y, Simon JA, Ou HC. Hair cell toxicity in anti-cancer drugs: evaluating an anti-cancer drug library for independent and synergistic toxic effects on hair cells using the zebrafish lateral line. J Assoc Res Otolaryngol. 2011;12(6):719-28. https://doi.org/10.1007/s10162-011-0278-z PMid:21732171 PMCid:PMC3214242
Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci. 2019;20(6):1451. https://doi.org/10.3390/ijms20061451 PMid:30909387 PMCid:PMC6471666
Starobova H, Vetter I. Pathophysiology of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci. 2017;10:174. https://doi.org/10.3389/fnmol.2017.00174 PMid:28620280 PMCid:PMC5450696
Caponero R, Montarroyos ES, Tahamtani SMM. Neuropatia pós-quimioterapia. Rev Dor. 2016;17(Suppl 1):56-8. https://doi.org/10.5935/1806-0013.20160049
Molassiotis A, Cheng HL, Leung KT, Li YC, Wong KH, Au JSK, et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav. 2019;9(6):e01312. https://doi.org/10.1002/brb3.1312 PMid:31063261 PMCid:PMC6576180
Lewis MA, Zhao F, Jones D, Loprinzi CL, Brell J, Weiss M, et al. Neuropathic symptoms and their risk factors in medical oncology outpatients with colorectal vs. breast, lung, or prostate cancer: results from a prospective multicenter study. J Pain Symptom Manage. 2015;49(6):1016-24. https://doi.org/10.1016/j.jpainsymman.2014.11.300 PMid:25596011 PMCid:PMC4479969
Hershman DL, Till C, Wright JD, Awad D, Ramsey SD, Barlow WE, et al. Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in southwest oncology group clinical trials. J Clin Oncol. 2016;34(25):3014-22. https://doi.org/10.1200/JCO.2015.66.2346 PMid:27325863 PMCid:PMC5012713
Kober KM, Olshen A, Conley YP, Schumacher M, Topp K, Smoot B, et al. Expression of mitochondrial dysfunction-related genes and pathways in paclitaxel-induced peripheral neuropathy in breast cancer survivors. Mol Pain. 2018;14:1744806918816462. https://doi.org/10.1177/1744806918816462 PMid:30426838 PMCid:PMC6293373
Komatsu H, Yagasaki K, Komatsu Y, Yamauchi H, Yamauchi T, Shimokawa T, et al. Falls and functional impairments in breast cancer patients with chemotherapy-induced peripheral neuropathy. Asia Pac J Oncol Nurs. 2019;6(3):253-60. https://doi.org/10.4103/apjon.apjon_7_19 PMid:31259221 PMCid:PMC6518979
Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, et al. Long-term peripheral neuropathy in breast cancer patients treated with adjuvant chemotherapy: NRG Oncology/NSABP B-30. J Natl Cancer Inst. 2018;110(2):djx162. https://doi.org/10.1093/jnci/djx162 PMCid:PMC5825682
Gebremedhn EG, Shortland PJ, Mahns DA. The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review. BMC Cancer. 2018;18(1):410. https://doi.org/10.1186/s12885-018-4185-0 PMid:29649985 PMCid:PMC5897924
Attili VS, Bapsy PP, Anupama G, Lokanatha D. Irreversible sensorineural hearing loss due to imatinib. Leuk Res. 2008;32(6):991-2. https://doi.org/10.1016/j.leukres.2007.11.039 PMid:18221994
Simsek G, Taş BM, Muluk NB, Azman M, Kılıç R. Comparison of the protective efficacy between intratympanic dexamethasone and resveratrol treatments against cisplatin-induced ototoxicity: an experimental study. Eur Arch Otorhinolaryngol. 2019;276(12):3287-93. https://doi.org/10.1007/s00405-019-05635-x PMid:31531774
Ding D, Allman BL, Salvi R. Review: ototoxic characteristics of platinum antitumor drugs. Anat Rec (Hoboken). 2018;295(11):1851-67. https://doi.org/10.1002/ar.22577 PMid:23044998
Tuknayat A, Thami GP, Gogia P, Bhutani M. Cyclophosphamide-induced hearing loss: reversibility and preventive strategies. Am J Ther. 2018;25(6):e692-5. https://doi.org/10.1097/MJT.0000000000000701 PMid:29232285
Oh SY, Wasif N, Garcon MC, Rodriguez G, Saif MW. Ototoxicity associated with oxaliplatin in a patient with pancreatic cancer. JOP. 2014;14(6):676-9. doi: https://doi.org/10.6092/1590-8577/1629
Schultz C, Goffi-Gomez MV, Liberman PH, Carvalho AL. Report on hearing loss in oncology. Braz J Otorhinolaryngol. 2009;75(5):634-41. https://doi.org/10.1590/S1808-86942009000500004 PMid:19893928
Fioretti A, Di Rubbo V, Peri G, Vitti E, Cisternino S, Varakliotis T, et al. Cochlear impairment and autoimmune ear disorder in a patient with breast cancer. Audiol Res. 2017;7(1):165. https://doi.org/10.4081/audiores.2017.165 PMid:28458811 PMCid:PMC5391518
Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O. Understanding platinum-induced ototoxicity. Trends Pharmacol Sci. 2013;34(8):458-69. https://doi.org/10.1016/j.tips.2013.05.006 PMid:23769626
Oliveira PF, Oliveira CS, Andrade JS, Santos TF, Oliveira-Barreto AC. Cancer treatment in determination of hearing loss. Braz J Otorhinolaryngol. 2016;82(1):65-69. https://doi.org/10.1016/j.bjorl.2014.12.010 PMid:26549572
Atas A, Agca O, Sarac S, Poyraz A, Akyol MU. Investigation of ototoxic effects of taxol on a mice model. Int J Pediatr Otorhinolaryngol. 2006;70(5):779-84. https://doi.org/10.1016/j.ijporl.2005.11.011 PMid:16406077
Sarafraz M, Ahmadi K. Paraclinical evaluation of side-effects of taxanes on auditory system Acta Otorhinolaryngol Ital [Internet]. 2008 [cited 2021 Feb 21];28(5):239-42. PMid: 19186452; PMCid: PMC2689535
de Freitas MR, de Castro Brito GA, de Carvalho JV Jr, Gomes RM Jr, Barreto Martins MJ, de Albuquerque Ribeiro R. Light microscopy study of cisplatin-induced ototoxicity in rats. J Laryngol Otol. 2009;123(6):590-7. https://doi.org/10.1017/S0022215109004319 PMid:19144244
Dong Y, Ding D, Jiang H, Shi JR, Salvi R, Roth JA. Ototoxicity of paclitaxel in rat cochlear organotypic cultures. Toxicol Appl Pharmacol. 2014;280(3):526-33. https://doi.org/10.1016/j.taap.2014.08.022 PMid:25181333
Ridwelski K, Gebauer T, Fahlke J, Kröning H, Kettner E, Meyer F, et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol. 2001;12:47-55. https://doi.org/10.1023/A:1008328501128 PMid:11249048
Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol. 2005;23:2937-45. https://doi.org/10.1200/JCO.2005.04.016 PMid:15728228
Han R, Yang YM, Dietrich J, Luebke A, Mayer-Pröschel M, Noble M. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol. 2008;7(4):12. https://doi.org/10.1186/jbiol69 PMid:18430259 PMCid:PMC2397490
Wang X, Han Y, Wang M, Bo C, Zhang Z, Xu L, et al. Wnt signaling protects against paclitaxel-induced spiral ganglion neuron damage in the mouse cochlea in vitro. Biomed Res Int. 2019;2019:7878906. https://doi.org/10.1155/2019/7878906 PMid:31687397 PMCid:PMC6800971
Bhandare N, Jackson A, Eisbruch A, Pan CC, Flickinger JC, Antonelli P, et al. Radiation therapy and hearing loss. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S50-7. https://doi.org/10.1016/j.ijrobp.2009.04.096 PMid:20171518 PMCid:PMC3319461
Upadhya I, Jariwala N, Datar J. Ototoxic effects of irradiation. Indian J Otolaryngol Head Neck Surg. 2011;63(2):151-154. https://doi.org/10.1007/s12070-011-0142-9 PMid:22468252 PMCid:PMC3102171
Theunissen EA, Bosma SC, Zuur CL, Spijker R, van der Baan S, Dreschler WA, et al. Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: a systematic review of the literature. Head Neck. 2015;37(2):281-92. https://doi.org/10.1002/hed.23551 PMid:24478269
Low WK, Kong SW, Tan MG. Ototoxicity from combined Cisplatin and radiation treatment: an in vitro study. Int J Otolaryngol. 2010;2010:523976. https://doi.org/10.1155/2010/523976 PMid:21151649 PMCid:PMC2995915
National Cancer Institute. National Institutes of Health, U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (Version 4.03) [Internet]. 2009 [published 2010 Jun 14; cited 2021 Feb 27]. Avaiable from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
Saito T, Zhang ZJ, Tokuriki M, Shibamori Y, Yamamoto T, Noda I, et al. Doxorubicin ototoxicity is induced in mice by combination treatment with cyclosporin A. Acta Otolaryngol. 2001;121:787-93. https://doi.org/10.1080/00016480152602212 PMid:11718240
Kerns SL, Fung C, Monahan PO, Ardeshir-Rouhani-Fard S, Abu Zaid MI, Williams AM, et al. Cumulative burden of morbidity among testicular cancer survivors after standard cisplatin-based chemotherapy: a multi-institutional study. J Clin Oncol. 2018;36(15):1505-12. https://doi.org/10.1200/JCO.2017.77.0735 PMid:29617189 PMCid:PMC5959198
Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695-704. https://doi.org/10.1056/NEJMoa071028 PMid:17960012
Miaskowski C, Paul SM, Mastick J, Abrams G, Topp K, Smoot B, et al. Associations between perceived stress and chemotherapy-induced peripheral neuropathy and otoxicity in adult cancer survivors. J Pain Symptom Manage. 2018;56(1):88-97. https://doi.org/10.1016/j.jpainsymman.2018.02.021 PMid:29524582 PMCid:PMC6015523
Miaskowski C, Paul SM, Mastick J, Schumacher M, Conley YP, Smoot B, et al. Hearing loss and tinnitus in survivors with chemotherapy-induced neuropathy. Eur J Oncol Nurs. 2018;32:1-11. https://doi.org/10.1016/j.ejon.2017.10.006 PMid:29353626 PMCid:PMC5783195
Bonhof CS, van de Poll-Franse LV, Vissers PAJ, Wasowicz DK, Wegdam JA, Révész D, et al. Anxiety and depression mediate the association between chemotherapy-induced peripheral neuropathy and fatigue: results from the population-based PROFILES registry. Psychooncology. 2019;28(9):1926-33. https://doi.org/10.1002/pon.5176 PMid:31293046 PMCid:PMC6771569
Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2020: incidência de Câncer no Brasil [Internet]. Rio de Janeiro: INCA; 2019 [cited 2020 Nov 20]. Available from: https://bit.ly/3kshkwy
Ferreira RC, Franco LFR. Efeitos colaterais decorrentes do tratamento quimioterápico no câncer de mama: revisão bibliográfica. Rev Univ Vale Rio Verde. 2017;15(2):633-8. https://doi.org/10.5892/ruvrd.v15i2.3759
Hirose Y, Simon JA, Ou HC. Hair cell toxicity in anti-cancer drugs: evaluating an anti-cancer drug library for independent and synergistic toxic effects on hair cells using the zebrafish lateral line. J Assoc Res Otolaryngol. 2011;12(6):719-28. https://doi.org/10.1007/s10162-011-0278-z PMid:21732171 PMCid:PMC3214242
Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci. 2019;20(6):1451. https://doi.org/10.3390/ijms20061451 PMid:30909387 PMCid:PMC6471666
Starobova H, Vetter I. Pathophysiology of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci. 2017;10:174. https://doi.org/10.3389/fnmol.2017.00174 PMid:28620280 PMCid:PMC5450696
Caponero R, Montarroyos ES, Tahamtani SMM. Neuropatia pós-quimioterapia. Rev Dor. 2016;17(Suppl 1):56-8. https://doi.org/10.5935/1806-0013.20160049
Molassiotis A, Cheng HL, Leung KT, Li YC, Wong KH, Au JSK, et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav. 2019;9(6):e01312. https://doi.org/10.1002/brb3.1312 PMid:31063261 PMCid:PMC6576180
Lewis MA, Zhao F, Jones D, Loprinzi CL, Brell J, Weiss M, et al. Neuropathic symptoms and their risk factors in medical oncology outpatients with colorectal vs. breast, lung, or prostate cancer: results from a prospective multicenter study. J Pain Symptom Manage. 2015;49(6):1016-24. https://doi.org/10.1016/j.jpainsymman.2014.11.300 PMid:25596011 PMCid:PMC4479969
Hershman DL, Till C, Wright JD, Awad D, Ramsey SD, Barlow WE, et al. Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in southwest oncology group clinical trials. J Clin Oncol. 2016;34(25):3014-22. https://doi.org/10.1200/JCO.2015.66.2346 PMid:27325863 PMCid:PMC5012713
Kober KM, Olshen A, Conley YP, Schumacher M, Topp K, Smoot B, et al. Expression of mitochondrial dysfunction-related genes and pathways in paclitaxel-induced peripheral neuropathy in breast cancer survivors. Mol Pain. 2018;14:1744806918816462. https://doi.org/10.1177/1744806918816462 PMid:30426838 PMCid:PMC6293373
Komatsu H, Yagasaki K, Komatsu Y, Yamauchi H, Yamauchi T, Shimokawa T, et al. Falls and functional impairments in breast cancer patients with chemotherapy-induced peripheral neuropathy. Asia Pac J Oncol Nurs. 2019;6(3):253-60. https://doi.org/10.4103/apjon.apjon_7_19 PMid:31259221 PMCid:PMC6518979
Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, et al. Long-term peripheral neuropathy in breast cancer patients treated with adjuvant chemotherapy: NRG Oncology/NSABP B-30. J Natl Cancer Inst. 2018;110(2):djx162. https://doi.org/10.1093/jnci/djx162 PMCid:PMC5825682
Gebremedhn EG, Shortland PJ, Mahns DA. The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review. BMC Cancer. 2018;18(1):410. https://doi.org/10.1186/s12885-018-4185-0 PMid:29649985 PMCid:PMC5897924
Attili VS, Bapsy PP, Anupama G, Lokanatha D. Irreversible sensorineural hearing loss due to imatinib. Leuk Res. 2008;32(6):991-2. https://doi.org/10.1016/j.leukres.2007.11.039 PMid:18221994
Simsek G, Taş BM, Muluk NB, Azman M, Kılıç R. Comparison of the protective efficacy between intratympanic dexamethasone and resveratrol treatments against cisplatin-induced ototoxicity: an experimental study. Eur Arch Otorhinolaryngol. 2019;276(12):3287-93. https://doi.org/10.1007/s00405-019-05635-x PMid:31531774
Ding D, Allman BL, Salvi R. Review: ototoxic characteristics of platinum antitumor drugs. Anat Rec (Hoboken). 2018;295(11):1851-67. https://doi.org/10.1002/ar.22577 PMid:23044998
Tuknayat A, Thami GP, Gogia P, Bhutani M. Cyclophosphamide-induced hearing loss: reversibility and preventive strategies. Am J Ther. 2018;25(6):e692-5. https://doi.org/10.1097/MJT.0000000000000701 PMid:29232285
Oh SY, Wasif N, Garcon MC, Rodriguez G, Saif MW. Ototoxicity associated with oxaliplatin in a patient with pancreatic cancer. JOP. 2014;14(6):676-9. doi: https://doi.org/10.6092/1590-8577/1629
Schultz C, Goffi-Gomez MV, Liberman PH, Carvalho AL. Report on hearing loss in oncology. Braz J Otorhinolaryngol. 2009;75(5):634-41. https://doi.org/10.1590/S1808-86942009000500004 PMid:19893928
Fioretti A, Di Rubbo V, Peri G, Vitti E, Cisternino S, Varakliotis T, et al. Cochlear impairment and autoimmune ear disorder in a patient with breast cancer. Audiol Res. 2017;7(1):165. https://doi.org/10.4081/audiores.2017.165 PMid:28458811 PMCid:PMC5391518
Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O. Understanding platinum-induced ototoxicity. Trends Pharmacol Sci. 2013;34(8):458-69. https://doi.org/10.1016/j.tips.2013.05.006 PMid:23769626
Oliveira PF, Oliveira CS, Andrade JS, Santos TF, Oliveira-Barreto AC. Cancer treatment in determination of hearing loss. Braz J Otorhinolaryngol. 2016;82(1):65-69. https://doi.org/10.1016/j.bjorl.2014.12.010 PMid:26549572
Atas A, Agca O, Sarac S, Poyraz A, Akyol MU. Investigation of ototoxic effects of taxol on a mice model. Int J Pediatr Otorhinolaryngol. 2006;70(5):779-84. https://doi.org/10.1016/j.ijporl.2005.11.011 PMid:16406077
Sarafraz M, Ahmadi K. Paraclinical evaluation of side-effects of taxanes on auditory system Acta Otorhinolaryngol Ital [Internet]. 2008 [cited 2021 Feb 21];28(5):239-42. PMid: 19186452; PMCid: PMC2689535
de Freitas MR, de Castro Brito GA, de Carvalho JV Jr, Gomes RM Jr, Barreto Martins MJ, de Albuquerque Ribeiro R. Light microscopy study of cisplatin-induced ototoxicity in rats. J Laryngol Otol. 2009;123(6):590-7. https://doi.org/10.1017/S0022215109004319 PMid:19144244
Dong Y, Ding D, Jiang H, Shi JR, Salvi R, Roth JA. Ototoxicity of paclitaxel in rat cochlear organotypic cultures. Toxicol Appl Pharmacol. 2014;280(3):526-33. https://doi.org/10.1016/j.taap.2014.08.022 PMid:25181333
Ridwelski K, Gebauer T, Fahlke J, Kröning H, Kettner E, Meyer F, et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol. 2001;12:47-55. https://doi.org/10.1023/A:1008328501128 PMid:11249048
Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol. 2005;23:2937-45. https://doi.org/10.1200/JCO.2005.04.016 PMid:15728228
Han R, Yang YM, Dietrich J, Luebke A, Mayer-Pröschel M, Noble M. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol. 2008;7(4):12. https://doi.org/10.1186/jbiol69 PMid:18430259 PMCid:PMC2397490
Wang X, Han Y, Wang M, Bo C, Zhang Z, Xu L, et al. Wnt signaling protects against paclitaxel-induced spiral ganglion neuron damage in the mouse cochlea in vitro. Biomed Res Int. 2019;2019:7878906. https://doi.org/10.1155/2019/7878906 PMid:31687397 PMCid:PMC6800971
Bhandare N, Jackson A, Eisbruch A, Pan CC, Flickinger JC, Antonelli P, et al. Radiation therapy and hearing loss. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S50-7. https://doi.org/10.1016/j.ijrobp.2009.04.096 PMid:20171518 PMCid:PMC3319461
Upadhya I, Jariwala N, Datar J. Ototoxic effects of irradiation. Indian J Otolaryngol Head Neck Surg. 2011;63(2):151-154. https://doi.org/10.1007/s12070-011-0142-9 PMid:22468252 PMCid:PMC3102171
Theunissen EA, Bosma SC, Zuur CL, Spijker R, van der Baan S, Dreschler WA, et al. Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: a systematic review of the literature. Head Neck. 2015;37(2):281-92. https://doi.org/10.1002/hed.23551 PMid:24478269
Low WK, Kong SW, Tan MG. Ototoxicity from combined Cisplatin and radiation treatment: an in vitro study. Int J Otolaryngol. 2010;2010:523976. https://doi.org/10.1155/2010/523976 PMid:21151649 PMCid:PMC2995915
National Cancer Institute. National Institutes of Health, U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (Version 4.03) [Internet]. 2009 [published 2010 Jun 14; cited 2021 Feb 27]. Avaiable from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
Saito T, Zhang ZJ, Tokuriki M, Shibamori Y, Yamamoto T, Noda I, et al. Doxorubicin ototoxicity is induced in mice by combination treatment with cyclosporin A. Acta Otolaryngol. 2001;121:787-93. https://doi.org/10.1080/00016480152602212 PMid:11718240
Kerns SL, Fung C, Monahan PO, Ardeshir-Rouhani-Fard S, Abu Zaid MI, Williams AM, et al. Cumulative burden of morbidity among testicular cancer survivors after standard cisplatin-based chemotherapy: a multi-institutional study. J Clin Oncol. 2018;36(15):1505-12. https://doi.org/10.1200/JCO.2017.77.0735 PMid:29617189 PMCid:PMC5959198
Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695-704. https://doi.org/10.1056/NEJMoa071028 PMid:17960012
Miaskowski C, Paul SM, Mastick J, Abrams G, Topp K, Smoot B, et al. Associations between perceived stress and chemotherapy-induced peripheral neuropathy and otoxicity in adult cancer survivors. J Pain Symptom Manage. 2018;56(1):88-97. https://doi.org/10.1016/j.jpainsymman.2018.02.021 PMid:29524582 PMCid:PMC6015523
Miaskowski C, Paul SM, Mastick J, Schumacher M, Conley YP, Smoot B, et al. Hearing loss and tinnitus in survivors with chemotherapy-induced neuropathy. Eur J Oncol Nurs. 2018;32:1-11. https://doi.org/10.1016/j.ejon.2017.10.006 PMid:29353626 PMCid:PMC5783195
Bonhof CS, van de Poll-Franse LV, Vissers PAJ, Wasowicz DK, Wegdam JA, Révész D, et al. Anxiety and depression mediate the association between chemotherapy-induced peripheral neuropathy and fatigue: results from the population-based PROFILES registry. Psychooncology. 2019;28(9):1926-33. https://doi.org/10.1002/pon.5176 PMid:31293046 PMCid:PMC6771569